Boston Scientific said net sales for Q2 2025 were $5.061 billion, growing 22.8% on a reported basis, 21.6% on an operational basis and 17.4% on an organic basis, all compared to the prior year period.

1. 01

   Boston Scientific said net sales for Q2 2025 were $5.061 billion, growing 22.8% on a reported basis, 21.6% on an operational basis and 17.4% on an organic basis, all compared to the prior year period.

2. 02

   The company reported GAAP net income attributable to Boston Scientific common stockholders of $797 million or $0.53 per share for Q2, compared to $324 million or $0.22 per share a year ago, and achieved adjusted EPS of $0.75, compared to $0.62 a year ago.

3. 03

   Boston Scientific said reported net sales growth for Q2 was 26.8% in Cardiovascular (organic 23.2%) and 15.7% in MedSurg (organic 7.0%), compared to the prior year period. Net sales were $3,345 million for Cardiovascular and $1,716 million for MedSurg.

4. 04

   The company estimates net sales growth for full year 2025 to be approximately 18 to 19% on a reported basis and 14 to 15% on an organic basis, compared to the prior year period. It estimates GAAP EPS in a range of $1.89 to $1.93 and adjusted EPS of $2.95 to $2.99.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.